Newron Pauses US Enrollment in Schizophrenia Trial After Sudden Death

Event summary

  • Newron Pharmaceuticals has paused enrollment of new patients in the US sites of its Phase III ENIGMA-TRS 2 study for evenamide, a treatment for treatment-resistant schizophrenia (TRS).
  • The pause follows the sudden death of a study participant outside the US; the investigator deemed the death unrelated to the study treatment.
  • An independent safety monitoring board has recommended the studies continue as designed, and ENIGMA-TRS 1, ongoing in 21 countries, remains active.
  • ENIGMA-TRS 2 has received regulatory approval in Argentina and India and is nearing approval in Colombia and Malaysia.
  • Newron expects to announce results from the 12-week primary endpoint assessment of ENIGMA-TRS 1 in QIV 2026.

The big picture

The pause in enrollment highlights the inherent risks associated with late-stage clinical trials, particularly in therapies targeting complex neurological conditions. Treatment-resistant schizophrenia carries a significantly elevated mortality risk, making patient safety paramount and increasing regulatory scrutiny. This event could delay Newron's potential entry into a market with significant unmet need and substantial commercial potential, given the limited treatment options currently available.

What we're watching

Regulatory Scrutiny
The FDA’s response and the information Newron provides will determine the timeline for resuming US enrollment, potentially impacting the trial’s overall duration and cost.
Clinical Trial Risk
Whether Newron can adequately address the FDA’s concerns and maintain patient confidence will be crucial for the successful completion of the ENIGMA-TRS program.
Market Perception
The incident and resulting pause could influence investor sentiment and the perceived risk profile of evenamide, potentially impacting Newron’s valuation.